Editas Medicine Reports Preclinical Data Demonstrating Robust Tumor Reduction and Clearance Using Novel, Engineered iNK Cells at the American Society of Hematology Annual Meeting

Written by Customer Service on December 12, 2021. Posted in Public Companies.

Preclinical data demonstrating Editas-engineered AsCas12a multiplexed editing of iPSCs enhances iNK tumor killing ability, supporting promise as a potential therapeutic approach for solid tumors iNKs with double knock-in of CD16 and mbIL-15 in combination with monoclonal antibodysignificantly reduce tumor burden iNKs with double knock-out of CISH and TGFβR2 substantially reduce tumor burden CAMBRIDGE, Mass., Dec. 12, 2021 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported in vitro and in vivo preclinical data on the enhanced tumor killing capacity of two modified induced pluripotent stem cell (iPSC)-derived natural killer (or iNK) cell therapies using Editas Medicine’s proprietary AsCas12a gene editing. The Company reported these findings in a presentation today at the 63rd...

Teladoc Health Is Providing Free Virtual Health Care Services to Those Impacted by Kentucky Tornadoes

Written by Customer Service on December 12, 2021. Posted in Public Companies.

PURCHASE, NY, Dec. 12, 2021 (GLOBE NEWSWIRE) — Teladoc Health (NYSE: TDOC), the global leader in whole-person virtual care, is providing free, 24/7 general medical telehealth visits to residents, first responders and others directly impacted by the devastating tornadoes in Kentucky. Individuals who are now being displaced can seek treatment from a licensed health care professional for any non-emergency illness by calling Teladoc directly at 855-225-5032. Among those adult and pediatric conditions that can be effectively diagnosed and treated as part of Teladoc’s general medical no-cost offering are common conditions including sinus problems, respiratory infections, allergies, cold and flu symptoms, and many other non-emergency illnesses. Individuals seeking physician-authorization for prescription refills of non-narcotic drugs...

Molecular Partners Confirms Ensovibep Retains Neutralization of Omicron Variant of SARS-CoV-2 in Preclinical Studies

Written by Customer Service on December 12, 2021. Posted in Public Companies.

Laboratory studies using full Omicron pseudovirus confirm ensovibep maintains ability to neutralize the variant with very high potency, relative to substantial reductions in neutralizing potency across numerous anti-SARS-CoV-2 antibody drugs Ensovibep continues to retain potent neutralization against all prior SARS-CoV-2 viral variants of concern, with an IC50 in the single digit ng/ml range Ensovibep is currently being evaluated in a global Phase 2-3 study (EMPATHY) in collaboration with Novartis ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 12, 2021 (GLOBE NEWSWIRE) — Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that preclinical studies confirm...

NexImmune Announces Preliminary Phase 1/2 NEXI-002 Results in Patients with Multiple Myeloma

Written by Customer Service on December 12, 2021. Posted in Public Companies.

Initial Phase 1/2 data presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition Phase 1/2 study of NEXI-002 as a monotherapy in patients with relapsed/refractory multiple myeloma patients who have failed ≥3 prior lines of therapy is ongoing GAITHERSBURG, Md., Dec. 12, 2021 (GLOBE NEWSWIRE) — NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced preliminary Phase 1/2 results from an ongoing study of NEXI-002, a patient-derived multi-antigen-specific CD8+ T cell treatment for patients with relapsed/refractory multiple myeloma who have failed ≥3 prior lines of therapy. The data on low doses of NEXI-002, presented at...

Verizon Response: unlimited call/text/data for parts of Kentucky, Illinois

Written by Customer Service on December 12, 2021. Posted in Public Companies.

For media: we have b-roll, pictures and additional information on our emergency response equipment available at our Emergency Resource Center – https://www.verizon.com/about/news/emergency-resource-center What you need to know: Verizon consumer (prepaid and postpaid) and small business* customers in parts of Kentucky and Illinois will receive unlimited calling, texting and data 12/12 through 12/18 Our Verizon Response team is available 24/7 to coordinate with first responders BASKING RIDGE, N.J., Dec. 12, 2021 (GLOBE NEWSWIRE) — For our consumer and small business customers impacted by tornadoes in parts of Kentucky and Illinois, beginning Sunday, December 12 through December 18, Verizon is providing unlimited calling, texting and data to those who reside in the following: Kentucky: Mayfield, Owensboro Illinois: The hardest...

Ennoconn Announces Definitive Agreement to Acquire NCR Budapest Manufacturing Facility

Written by Customer Service on December 12, 2021. Posted in Mergers And Acquisitions.

NEW TAIPEI CITY, Taiwan, Dec. 12, 2021 (GLOBE NEWSWIRE) — Ennoconn Corporation (Taiwan Exchange / 6414.TW), a global leader in integrated cloud management services, Industrial IoT and embedded technology, today announced a definitive agreement to acquire NCR’s Budapest manufacturing facility, including physical assets, personnel, and the transfer of manufacturing responsibilities. This transaction allows Ennoconn Corporation, a financial subsidiary of Foxconn, to significantly expand their footprint in Europe by acquiring NCR’s World Class manufacturing, integration and assembly operations in Budapest. Ennoconn plans to continue to produce ATM, self-checkout (SCO) and point of sale (POS) solutions for NCR’s European Banking and Retail customer demand. “Ennoconn will utilize this facility and additional resources to advance manufacturing...

Sana Biotechnology Presentations at 2021 ASH Annual Meeting Highlight Progress with Platforms and CAR T Cell Programs

Written by Customer Service on December 12, 2021. Posted in Public Companies.

Hypoimmune CAR T cells evade both innate and adaptive immune systems in murine models, even in animals with pre-existing immunity to CAR T cells CD8- and CD4-targeted fusosomes generated functional CAR T cells in vivo, demonstrating T cell-specific delivery and therapeutic function in animal models SEATTLE, Dec. 12, 2021 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, presented data at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from Saturday, December 11 to Tuesday, December 14, 2021, which highlighted further progress with key technologies supporting Sana’s in vivo and ex vivo CAR T cell programs. “The data presented at ASH showcase the progress we are making with Sana’s CAR T cell programs,” said...

New Data from SLN124 Healthy Volunteer Study Reinforce Broad Therapeutic Potential in Hematological Diseases

Written by Customer Service on December 12, 2021. Posted in Public Companies.

New Data from SLN124 Healthy Volunteer Study Reinforce Broad Therapeutic Potential in Hematological Diseases Data presented at 2021 ASH annual meeting showed durable reductions in serum iron and transferrin saturation, strong safety profile and long duration of action Data support ongoing studies in patients with thalassemia and myelodysplastic syndrome and a new planned study in polycythemia vera 12 December 2021 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today presented additional positive data from the SLN124 healthy volunteer study at the 2021 American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia (USA)....

ALX Oncology Announces Initial Data from ASPEN-02, the Ongoing Phase 1 / 2 Study of Evorpacept in Combination with Azacitidine, Demonstrating Safety and Preliminary Activity in Patients with Myelodysplastic Syndrome

Written by Customer Service on December 12, 2021. Posted in Public Companies.

— Complete remissions with cytogenetic responses, hematologic improvement, and transfusion independence were observed in patients with previously untreated higher-risk MDS — Objective responses were observed in patients with relapsed/refractory MDS that had progressed after prior hypomethylating agents — No exacerbation of cytopenias and no dose limiting toxicities observed in combination with azacitidine — ALX Oncology to Host Conference Call on December 13th at 8:00 a.m. EST SOUTH SAN FRANCISCO, Calif., Dec. 12, 2021 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced the presentation of initial clinical data from its ongoing trial evaluating evorpacept in combination...

Nurix Therapeutics Announces Regulatory Clearance to Initiate Phase 1 Clinical Trial of NX-5948 and Presents New Preclinical Data at the American Society of Hematology Annual Meeting

Written by Customer Service on December 12, 2021. Posted in Public Companies.

U.K. regulatory authorities grant Clinical Trial Authorization with dosing of first patient anticipated in the first half of 2022 NX‑5948 crosses the blood‑brain barrier in preclinical models enabling potential dual development in oncology and autoimmune diseases of the central nervous system NX‑5948 reduces tumor burden and extends survival in a preclinical model of primary central nervous system lymphoma SAN FRANCISCO, Dec. 12, 2021 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the grant of a Clinical Trial Authorization (CTA) for NX-5948, a potent and selective degrader of Bruton’s tyrosine kinase (BTK) and the second drug candidate in Nurix’s BTK degradation program. The authorization was granted by the U.K. Medicines &...

Day: December 12, 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice